ReviewStem cell research & therapy2025
Stem cell-derived exosomes in complicated urinary tract infections: immunomodulatory mechanisms and potential therapeutic strategies for urothelial repair.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complicated urinary tract infection (cUTI), characterized by recurrent episodes due to multidrug-resistant bacterial infections and biofilm formation, severely compromises patients' quality of life. Although uropathogenic Escherichia coli remains the primary pathogen, its ability to form biofilms and induce persistent inflammatory responses exacerbates urothelial damage, thereby aggravating the disease. Current antibiotic treatments face resistance issues and inability to promote tissue repair, emphasizing the need for innovative treatments. Stem cell-derived exosomes have emerged as a promising solution for cUTI treatment due to their unique anti-inflammatory and tissue-repairing properties. In addition, advancements in targeted drug delivery and biomaterial integration have increased drug stability and therapeutic precision. These innovations have the potential to revolutionize the treatment of multidrug-resistant bacterial infections and the repair of complicated tissue damage, offering improved patient outcomes and addressing the limitations of traditional therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.